LM-302 for Solid Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called LM-302 in patients with advanced cancers that have a specific protein called CLDN18.2. The drug aims to attach to this protein on cancer cells to help stop their growth. Another drug targeting the same protein has been developed and tested in previous studies.
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Adults (18+) with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. Participants must be informed about the trial and willing to sign consent, have a life expectancy of at least 3 months, an ECOG performance status of 0-1, and appropriate organ function. CLDN18.2 positive status may be required for certain phases.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dose escalation of LM-302 every 3 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for long-term safety and effectiveness
Treatment Details
Interventions
- LM-302
Find a Clinic Near You
Who Is Running the Clinical Trial?
LaNova Medicines Limited
Lead Sponsor
Turning Point Therapeutics, Inc.
Lead Sponsor